drugset / Trial / NCT00839449

Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study

NCT00839449

RandomizedParallel-groupOpen-labelPrevention

Summary

Cerebral vasospasm following subarachnoid hemorrhage (SAH) is the most common cause of morbidity and mortality. Recent studies indicate that Rho-kinase play an important role in the occurrence of such cerebral vasospasm. Eicosapentaenoic acid (EPA) inhibits sphingosylphosphorylcholine (SPC)-induced Rho-kinase activation in vitro. So this study examines whether EPA prevents cerebral vasospasm occurrence after SAH in patients.

Timeline

Start
2004-12
Primary completion
2008-06
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject icosapent ethyl Small molecule 900 mg Oral